Formycon AG, which specialises in developing biosimilar medicines for third parties, has appointed Bernhard Hampl to its advisory board. Dr Hampl was previously chief executive of EON LABS Inc and later the US unit of Sandoz (Novartis). He holds a doctorate in pharmaceutical chemistry and currently advises pharmaceutical, biotechnology and investment companies.
Formycon announced the appointment on 13 March 2014.
Copyright 2014 Evernow Publishing Ltd